Please assess the completion status of the following clinical trial:

Trial Title: Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cerebral cavernous malformations-common Hispanic mutation (CCM1-CHM)~* Must be willing to travel to the University of New Mexico in Albuquerque, NM for 5 visits over the course of three months.~Exclusion Criteria:~* Incarceration~* Unable to pass MRI safety screening (pregnant females, claustrophics, or those with certain metallic items implanted in their bodies)~* Low kidney function or transplants, an eGFR below 60 mL/min~* Currently taking statin medications or have taken statin medications in the past 6 months~* Known allergy or intolerance to statins~* Known allergy or intolerance to gadolinium~* Liver dysfunction at baseline, AST \> 47 and/or ALT \> 49~* Consumption of large quantities of alcohol, men who consume more than 2 daily drinks and women who consume more than one daily drink~* CK level of 232 or higher~* Triglycerides greater than or equal to 500.~* Medications: gemfibrozil, cyclosporine, danazol, itraconazole, ketoconazole, posaconazole, ethromycin, clarithomycin, telithromycin, HIV protease inhibitors, nefazoldone, amiodarone, verapamil, dilitiazem, amlodipine, or ranalazine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simvastatin (Type: EXPERIMENTAL): 20-40 mg tablet taken daily by mouth. Month 1: 20 mg; Months 2 and 3: 40 mg.
- No Treatment (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).